scholarly journals Expression of programmed death-ligand 1 and programmed death-1 in patients with extramammary paget's disease

2021 ◽  
Vol 66 (2) ◽  
pp. 169
Author(s):  
Hiroyuki Goto ◽  
Kazunari Sugita ◽  
Osamu Yamamoto
Keyword(s):  
Paget’S Disease ◽  
Paget's Disease ◽  
Extramammary Paget’S Disease ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Programmed Death 1 ◽  
Extramammary Paget's Disease

Programmed Death-Ligand 1 and Programmed Death-Ligand 2 Expression Can Affect Prognosis in Extramammary Paget’s Disease

2021 ◽  
Vol 41 (1) ◽  
pp. 219-226
Author(s):  
AYA KAWAGUCHI ◽  
JUN AKIBA ◽  
REIICHIRO KONDO ◽  
EIJI SADASHIMA ◽  
SACHIKO OGASAWARA ◽  
...  
Keyword(s):  
Paget’S Disease ◽  
Paget's Disease ◽  
Extramammary Paget’S Disease ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Extramammary Paget's Disease

Four cases of extramammary Paget's disease - A topographic study.

1984 ◽  
Vol 46 (5) ◽  
pp. 1118-1122 ◽  
Author(s):  
Yoshihisa FUJII ◽  
Nobuyuki SHIRAISHI ◽  
Etsuji MATSUNAGA ◽  
Susumu TAKAYASU ◽  
Toshitaka NAKAMURA
Keyword(s):  
Paget’S Disease ◽  
Paget's Disease ◽  
Extramammary Paget’S Disease ◽  
Extramammary Paget's Disease

A Case of Extramammary Paget's Disease after Excision of Bilateral Breast Carcinoma

2007 ◽  
Vol 69 (3) ◽  
pp. 273-276
Author(s):  
Satoko KUMAZAWA ◽  
Kou DAN ◽  
Teiichi MASUDA ◽  
Kazunori URABE ◽  
Masutaka FURUE
Keyword(s):  
Breast Carcinoma ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Extramammary Paget’S Disease ◽  
Bilateral Breast Carcinoma ◽  
Extramammary Paget's Disease

Impact of Surgery on Extramammary Paget’s Disease Vulva: a Case Series

2021 ◽  
Author(s):  
J. S. Anjana ◽  
P. Rema ◽  
S. Suchetha ◽  
J. Siva Ranjith ◽  
Amrita B. Rao ◽  
...  
Keyword(s):  
Paget’S Disease ◽  
Case Series ◽  
Paget's Disease ◽  
Extramammary Paget’S Disease ◽  
Extramammary Paget's Disease

scholarly journals A Positive Dermcidin Expression Is an Unfavorable Prognostic Marker for Extramammary Paget’s Disease

Diagnostics ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 1086
Author(s):  
Shun Ohmori ◽  
Yu Sawada ◽  
Natsuko Saito-Sasaki ◽  
Sayaka Sato ◽  
Yoko Minokawa ◽  
...  
Keyword(s):  
Overall Survival ◽  
Therapeutic Option ◽  
Univariate Analysis ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Positive Staining ◽  
Extramammary Paget’S Disease ◽  
Potential Biomarker ◽  
The Impact ◽  
Extramammary Paget's Disease

Extramammary Paget’s disease is recognized as an apocrine-origin cutaneous tumor and is localized in the intraepithelial skin lesion. However, its advanced form is intractable, and there is currently no therapeutic option with a satisfactory level of clinical outcome. Therefore, it is of great importance to identify a potential biomarker to estimate tumor advancement in extramammary Paget’s disease. Dermcidin is an antimicrobial peptide derived from the eccrine gland and is identified as a biomarker in various malignancies. To investigate the potential of dermcidin in extramammary Paget’s disease, we investigated dermcidin expression in tumors using the immunostaining technique. Although previous studies have reported that extramammary Paget’s disease has no positive staining against dermcidin, 14 out of 60 patients showed positive staining of dermcidin in our study. To clarify the characteristics of positive dermcidin in extramammary Paget’s disease, we investigated the clinical characteristics of positive dermcidin extramammary Paget’s disease patients. Positive dermcidin patients showed a significantly high frequency of lymph node metastasis. We next investigated the impact of positive dermcidin on overall survival. Univariate analysis identified that positive dermcidin showed a significantly increased hazard ratio in overall survival, suggesting that dermcidin might be a prognostic factor for extramammary Paget’s disease.

scholarly journals The Outcome of Chemotherapy for Metastatic Extramammary Paget’s Disease

2021 ◽  
Vol 10 (4) ◽  
pp. 739
Author(s):  
Hiroki Hashimoto ◽  
Yumiko Kaku-Ito ◽  
Masutaka Furue ◽  
Takamichi Ito
Keyword(s):  
Adverse Events ◽  
Response Rate ◽  
Paget’S Disease ◽  
Progression Free Survival ◽  
Paget's Disease ◽  
Extramammary Paget’S Disease ◽  
Conventional Chemotherapy ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Extramammary Paget's Disease

The efficacy and survival impact of conventional chemotherapies for metastatic extramammary Paget’s disease (EMPD) have not been fully elucidated. This study examined the long-term outcome of chemotherapy for this indication. We conducted a retrospective review of 21 patients with distant metastatic EMPD (14 patients treated with chemotherapy and 7 patients treated without chemotherapy). The response rate of chemotherapy and patient survival were statistically analyzed. Among the 14 patients treated with chemotherapy, 12, 1, and 1 patient received docetaxel, paclitaxel, and low-dose 5-fluorouracil plus cisplatin, respectively, as the first-line treatment. The response rate was 50.0% (7/14), and the disease control rate was 64.3% (9/14). The median progression-free survival (PFS) and overall survival (OS) were 16.8 and 27.9 months, respectively. Multivariate analyses revealed that chemotherapy was a significant factor for prolonged PFS (hazard ratio (HR) 0.22, p = 0.038) but not for OS (HR = 1.71, p = 0.54). Ten patients (71.4%) had severe (grade 3 or 4) hematological adverse events. Although conventional chemotherapy improved PFS, we failed to show a significantly improved OS. Considering the frequent adverse events of conventional chemotherapy, targeted therapy may become a mainstay for the treatment of metastatic EMPD.

Sign in / Sign up

Export Citation Format

Share Document